The NPM1 mutation, typically a favorable prognostic marker in newly diagnosed AML, loses this advantage in the relapsed/refractory setting. Survival for relapsed NPM1 patients becomes as poor as for those without the mutation, justifying aggressive targeted therapy with menin inhibitors.

A major limitation of menin inhibitor monotherapy is acquired resistance. Up to 39% of patients on revumenib develop mutations in the menin (MEN1) gene. These mutations prevent the drug from binding to its target, leading to rapid relapse and highlighting the need for combination therapies or next-generation agents.

While MEN1 mutations cause resistance, they don't explain all treatment failures, especially with agents like Ziftomenib. Other mechanisms, including activation of RTK pathways (RAS, FLT3) and epigenetic bypass, are key drivers of acquired resistance.

Combinations of menin inhibitors with standard chemotherapy are achieving impressively high remission rates (e.g., 89% composite remission) in newly diagnosed KMT2A-rearranged AML. This is a significant development, as this genetic subtype has historically been very challenging to treat effectively.

Similar to FLT3 inhibitors like midostaurin, which failed in the relapsed setting but succeeded upfront, menin inhibitors are expected to show dramatically better efficacy when combined with standard induction or HMA/Venetoclax in newly diagnosed patients.

Preclinical data and early clinical findings suggest menin inhibitors could be effective against rare NUP98-rearranged leukemias. This is based on similarities in downstream pathways to the approved KMT2A and NPM1 mutations, hinting at a broader mechanism of action for this drug class.

Unlike typical targeted therapies that block a mutated receptor, menin inhibitors work by disrupting a master transcription complex. This forces leukemic cells to mature (differentiate) into terminal forms like neutrophils, after which they naturally die off.

The new menin inhibitor, enzomenib, demonstrates potentially superior response rates (CR/CRH of 40-60%) compared to existing agents (~23%). Crucially, early data shows no QTc prolongation, a significant dose-limiting toxicity for current menin inhibitors, suggesting a major safety improvement for this drug class.

The Spanish KIWI trial showed a surprising survival benefit for quizartinib in FLT3-ITD negative AML. The benefit was greatest in patients with NPM1 and DNMT3A mutations, suggesting the drug's efficacy extends beyond its primary target through other mechanisms.